Richard A. Gonzalez

Richard A. Gonzalez spent his entire professional career inside Abbott Laboratories before becoming AbbVie's founding Chairman and CEO. He joined Abbott in 1977 as a process engineer and rose through manufacturing, operations, and pharmaceutical business leadership roles over more than three decades. By the time the AbbVie separation was being planned in 2011 and 2012, Gonzalez was serving as executive vice president and president of Abbott's global pharmaceutical business, making him the natural selection to lead the new independent company. His deep operational familiarity with Humira's manufacturing, regulatory, and commercial infrastructure gave him an unusual combination of scientific understanding and commercial acumen.

Richard A. Gonzalez was born and educated in the United States, earning a degree in science from the University of Houston. He joined Abbott Laboratories in 1977 and spent 35 years building expertise across pharmaceutical manufacturing, research operations, and commercial leadership before leading the spin-off that created AbbVie. As AbbVie's founding and continuing CEO, Gonzalez has presided over the company's entire history: the Humira peak, the Pharmacyclics acquisition, the Allergan mega-deal, the biosimilar transition, and the construction of the Skyrizi-Rinvoq platform. Under his leadership, AbbVie's market capitalization grew from approximately $54 billion at spin-off to over $320 billion by mid-2025. Gonzalez has been recognized repeatedly on Fortune's list of most powerful executives in business and has testified before Congress on pharmaceutical pricing policy. His tenure represents one of the longest continuous CEO runs of any large-cap pharmaceutical company in the contemporary era.